title: Expression of CD147 is associated with prostate cancer progression.
abstract: Novel molecular markers that are associated with prostate cancer (PCa) progression will provide valuable information in the diagnosis and treatment of the disease. Extracellular matrix metalloproteinase inducer (CD147) has been demonstrated to be involved in tumor invasion, metastasis, growth and survival. In our study, we examined whether the expression of CD147 can be used as a prognostic marker for predicting PCa progression. Tissue samples from 240 patients who received radical prostatectomy for PCa were obtained. CD147 expression in these samples was evaluated using immunohistochemical staining with a monoclonal antibody specifically against CD147. Increased expression of CD147 was correlated with higher Gleason scores (GS), positive surgical margin, prostate-specific antigen (PSA) failure, metastasis and reduced overall survival. Both univariate Cox regression analysis and multivariate analysis including competing biological variables demonstrated that increased CD147 expression was associated with increased risk for reduced PSA failure-free, metastasis-free and overall survival. Kaplan-Meier survival curves showed that the CD147 overexpression was a significant predictor for the PSA failure-free, metastasis-free and the overall survival in both pT2 and pT3 PCa patients. More significantly, higher expression of CD147 can serve as an independent prognostic predictor for PSA failure-free survival in PCa patients when they are stratified by GS. Our study results demonstrate the involvement of CD147 in PCa progression and suggest its potential role as an independent predictor of biochemical recurrence, development of metastasis and reduced overall survival in PCa.
authors.affiliation: Department of Urology, Guangzhou First Municipal People's Hospital, Guangzhou Medical College, Guangzhou, China.
authors.forename: Wei-de
authors.initials: WD
authors.lastname: Zhong
authors.forename: Yu-Xiang
authors.initials: YX
authors.lastname: Liang
authors.forename: Sharron X
authors.initials: SX
authors.lastname: Lin
authors.forename: Ling
authors.initials: L
authors.lastname: Li
authors.forename: Hui-Chan
authors.initials: HC
authors.lastname: He
authors.forename: Xue-Cheng
authors.initials: XC
authors.lastname: Bi
authors.forename: Zhao-Dong
authors.initials: ZD
authors.lastname: Han
authors.forename: Qi-Shan
authors.initials: QS
authors.lastname: Dai
authors.forename: Yong-Kang
authors.initials: YK
authors.lastname: Ye
authors.forename: Qing-Biao
authors.initials: QB
authors.lastname: Chen
authors.forename: Yue-Sheng
authors.initials: YS
authors.lastname: Wang
authors.forename: Guo-Hua
authors.initials: GH
authors.lastname: Zeng
authors.forename: Gang
authors.initials: G
authors.lastname: Zhu
authors.forename: Zheng
authors.initials: Z
authors.lastname: Zhang
authors.forename: Zhi-Nan
authors.initials: ZN
authors.lastname: Chen
authors.forename: Chin-Lee
authors.initials: CL
authors.lastname: Wu
mesh_terms: D051926:Basigin / Q000096:biosynthesis*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D016896:Treatment Outcome
chemical_list: C497886:BSG protein, human; D051926:Basigin